Results 131 to 140 of about 88,754 (289)

Assessment of the availability of repurposed orphan drugs in India. [PDF]

open access: yesPLOS Glob Public Health, 2023
Rajueni K, Chakraborty Choudhury M.
europepmc   +1 more source

Two-stage public-private partnership proposal for R&D on neglected diseases [PDF]

open access: yes
We propose a 2-stage procurement model of public-private partnership to provide better incentives for R&D on neglected diseases. The model combines advance market commitment, subsidized clinical trials, and rewards based on therapeutical contributions of
Brigitte Granville, Eshref Trushin
core  

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

open access: yesMed Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang   +22 more
wiley   +1 more source

Orphan drugs

open access: yesArbor: Ciencia, Pensamiento y Cultura, 2018
Orphan drugs are intended for the treatment of diseases of low prevalence, also known as rare diseases. Research and development into new therapies for this heterogeneous group of diseases presents a number of well-recognized difficulties. One of these is that the small number of patients affected jeopardizes the economic return on the investment made ...
Fontanet Sacristán, Juan Manuel   +1 more
openaire   +1 more source

Social Security Programs Throughout the World: The Americas, 2011 [PDF]

open access: yes, 2012
[Excerpt] This fourth issue in the current four-volume series of Social Security Programs Throughout the World reports on the countries of the Americas.
International Social Security Association   +1 more
core   +1 more source

Engineering compact Physalis peruviana (goldenberry) to promote its potential as a global crop

open access: yesPLANTS, PEOPLE, PLANET, EarlyView.
Goldenberry (Physalis peruviana) produces sweet, nutritionally rich berries, yet like many minor crops, is cultivated in limited geographical regions and has not been a focus of breeding programs for trait enhancement. Leveraging knowledge of plant architecture‐related traits from related species, we used CRISPR/Cas9‐mediated gene editing to generate a
Miguel Santo Domingo   +8 more
wiley   +1 more source

Transformers: African American Women Leaders in the Pharmaceutical Industry [PDF]

open access: yes, 2016
This qualitative study documents the experiences of African American women leaders in the pharmaceutical industry in the context of the transformative leadership model. Transformative leadership is a theory that recognizes that the success of individuals
Bonaparte, Yvette Lynne
core   +1 more source

Utilization and affordability of health insurance coverage for rare disease drugs in a first-tier city in Northeast China from 2018 to 2021: a study based on the health insurance claims database

open access: yesInternational Journal for Equity in Health
Objective The accessibility issue of orphan drugs in China is prominent. Based on real-world data from a tier-one city in Northeast China, this study aims to analyze the current usage and affordability of orphan drugs for rare diseases.
Yaqun Wang   +6 more
doaj   +1 more source

Association of autoimmune diseases with biologic agents targeting type 2 immunity: An observational study using a claims database

open access: yesRheumatology &Autoimmunity, EarlyView.
This observational study assessed the association between anti‐type 2 biologic agents and the occurrence of autoimmune diseases using a large real‐world claims database. Anti‐IL‐5 and anti‐IgE therapies were associated with an increased occurrence of autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE ...
Shoichiro Inokuchi
wiley   +1 more source

Orphan Drugs in Neurology-A Narrative Review. [PDF]

open access: yesJ Pers Med, 2023
Sirbu CA   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy